AstraZeneca PLC (AZN.L) News Headlines

▮ More

Date

Headline

9/17/2021 7:54:22 AM AZN : Imfinzi Plus Novel Immunotherapies Improve Clinical Outcomes For Patients With Lung Cancer

9/17/2021 7:35:18 AM AstraZeneca Announces COAST Phase II Trial Results

9/9/2021 12:13:56 PM AstraZeneca Reports Positive Results From Late-stage Trial For Lung Cancer Treatment

9/9/2021 11:07:09 AM AstraZeneca's IMFINZI And Tremelimumab With Chemotherapy Improve PFS By 28% In 1st-line Stage IV NSCLC

9/9/2021 2:32:10 AM AstraZeneca: MANDALA, DENALI Phase III Trials Of PT027 For Asthma Meet All Primary Goals

9/9/2021 2:05:30 AM AstraZeneca Says MANDALA And DENALI Phase III Trials Of PT027 Meet All Primary Endpoints

9/8/2021 7:57:38 AM Hutchmed Says First Patient Dosed In China Phase III Trial Of Orpathys And Tagrisso In Lung Cancer

9/8/2021 6:58:34 AM HUTCHMED, AstraZeneca Initiate SANOVO Phase III Trial Of ORPATHYS And TAGRISSO Combination For Lung Cancer In China

9/5/2021 10:56:35 AM Amgen's Tezepelumab Reduces Exacerbations In Patients With Severe Asthma & Comorbid Nasal Polyps

9/3/2021 5:14:32 AM EU, AstraZeneca Agree On Delivery Of Remaining 200 Mln COVID-19 Vaccine Doses

9/3/2021 2:14:32 AM AstraZeneca: European Commission Approves Expanded Use Of Ultomiris For Children, Adolescents

9/3/2021 2:03:50 AM AstraZeneca's Ultomiris Approved In EU For Expanded Use To Include Children In Paroxysmal Nocturnal Haemoglobinuria

8/31/2021 7:45:14 AM AstraZeneca's FLUMIST QUADRIVALENT Available For Flu Vaccination - Quick Facts

8/26/2021 2:41:33 AM AstraZeneca's Forxiga Approved In Japan For Chronic Kidney Disease - Quick Facts

8/26/2021 2:35:08 AM AstraZeneca : Phase III Trial In Wilson Disease Meets Primary Endpoint

8/26/2021 2:12:17 AM AstraZeneca: Forxiga Approved In Japan For Chronic Kidney Disease In Patients With And Without Type-2 Diabetes

8/26/2021 2:05:46 AM AstraZeneca Says ALXN1840 FoCus Phase III Trial In Wilson Disease Meets Primary Endpoint

8/20/2021 2:48:48 AM AstraZeneca: Alexion To Discontinue CHAMPION-ALS Phase 3 Trial Of Ultomiris In ALS

8/20/2021 2:26:52 AM AstraZeneca : Phase III Trial On AZD7442 Meets Primary Endpoint In Preventing COVID-19

8/20/2021 2:06:33 AM AstraZeneca Says AZD7442 Prophylaxis Trial Meets Primary Endpoint

Astrazeneca Plc (AZN.L)